Last update 27 Jun 2026

HX011

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
HX011
Target
OX40
Action
agonists
Mechanism
OX40 agonists(Tumor necrosis factor receptor superfamily member 4 agonists)
Therapeutic Areas
NeoplasmsDigestive System DisordersRespiratory Diseases+ [1]
Active Indication
Advanced Malignant Solid NeoplasmColonic CancerLung Cancer+ [3]
Inactive Indication-
Originator Organization
Hangzhou Hansi Biological Pharmaceutical Co., Ltd.
Active Organization
Wuhan HouXian Biomedical Co., Ltd.Hangzhou Hansi Biological Pharmaceutical Co., Ltd.
Inactive Organization-
License Organization-
Drug Highest PhasePhase 1
First Approval Date-
Regulation-
Login to view timeline

Related

1
Clinical Trials associated with HX011
CTR20262433
/ Not yet recruitingPhase 1
评价HX011注射液治疗晚期实体瘤患者的安全性、耐受性和初步疗效的开放、非随机、剂量递增的I期临床试验
[Translation] An open-label, non-randomized, dose-escalation phase I clinical trial evaluating the safety, tolerability, and preliminary efficacy of HX011 injection in patients with advanced solid tumors.
100 Clinical Results associated with HX011
Login to view more data
100 Translational Medicine associated with HX011
Login to view more data
100 Patents (Medical) associated with HX011
Login to view more data
100 Deals associated with HX011
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Advanced Malignant Solid NeoplasmPhase 1
China
Wuhan HouXian Biomedical Co., Ltd.
24 Jun 2026
Colonic CancerIND Approval
China
Wuhan HouXian Biomedical Co., Ltd.
15 Apr 2026
Lung CancerIND Approval
China
Wuhan HouXian Biomedical Co., Ltd.
15 Apr 2026
MelanomaIND Approval
China
Wuhan HouXian Biomedical Co., Ltd.
15 Apr 2026
Triple Negative Breast CancerIND Approval
China
Wuhan HouXian Biomedical Co., Ltd.
15 Apr 2026
NeoplasmsPreclinical
China
Hangzhou Hansi Biological Pharmaceutical Co., Ltd.
19 Apr 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
view full example data
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free